SMIP 004

Key Product Details

Product Description

SMIP 004 is an SKP2 (S-phase kinase-associated protein 2) inhibitor. Upregulates p27 and activates the unfolded protein response (UPR) in LNCaP prostate cancer cells overexpressing SKP2. Also induces oxidative stress. Induces proteasomal degradation of cyclin D1 and acts as CDK2 inhibitor. Arrests cell cycle in G₁ phase and induces apoptosis in prostate cancer cells, but not normal cells in vitro. Inhibits growth of breast and prostate cancer xenografts in mice. Also induces autophagy and reduces replication of MERS-CoV in VeroB4 cells.

Product Specifications for SMIP 004

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SMIP 004

The following data is based on the product molecular weight 205.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.87 mL	24.35 mL	48.71 mL
5 mM	0.97 mL	4.87 mL	9.74 mL
10 mM	0.49 mL	2.44 mL	4.87 mL
50 mM	0.10 mL	0.49 mL	0.97 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Rico-Bautista Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling. Oncotarget 2013 PMID: 23902736
• Gassen SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat.Commun. 2019 PMID: 31852899
• Rico-Bautista Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol. 2010 PMID: 21182779

Product Documents for SMIP 004